Amundi Arcus Biosciences, Inc. Transaction History

Amundi

6 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2025 May 15, 2025	SELL	$7.85 - $15.24 $23,840 - $46,283	-3,037 Reduced 11.24%	23,993 $188,000
Q4 2024 Feb 07, 2025	BUY	$14.28 - $18.44 $223,110 - $288,106	15,624 Added 136.98%	27,030 $402,000
Q3 2024 Nov 13, 2024	BUY	$13.69 - $18.01 $13,881 - $18,262	1,014 Added 9.76%	11,406 $174,000
Q2 2024 Aug 14, 2024	BUY	$14.59 - $18.48 $12,051 - $15,264	826 Added 8.63%	10,392 $158,000
Q1 2024 May 15, 2024	BUY	$14.83 - $20.18 $42,309 - $57,573	2,853 Added 42.5%	9,566 $180,000

Q2 2023 Aug 14, 2023	BUY	$16.97 - $22.03 $113,919 - $147,887	6,713 New	6,713 $136,000

212

67.7M

3.3M

146K

Ticker RCUS
Exchange NYSE
Sector Healthcare
Industry Biotechnology
Shares Outstandng 72,160,000
Market Cap $1.45B
Description
Arcus Biosciences, Inc., a clinical-stage biopharmaceutical company, develops and commercializes cancer therapies in the United States. Its product pipeline includes, Etrumadenant, a dual A2a/A2b adenosine receptor antagonist, which is in a Phase 1b/2 clinical trial; and Zimberelimab, an anti-PD-1 antibody that is in Phase 1b clinical trial for ...

Get notified when there are updates to the investment portfolio of Amundi, based on Form 13F filings with the SEC.

Stay updated on Amundi with notifications on news.